STE STERIS plc Insider Trading

CEO Daniel A Carestio sells 4,428 shares of STE for $946,798.56 via scheduled 10b5-1 plan

Daniel A Carestio, President and CEO of STERIS plc, executed 2 separate sales totaling 4,428 shares for $946,798.56 on 2026-06-04 and 2026-06-05 at blended average price $213.82. The transaction is part of a pre-arranged 10b5-1 trading plan, meaning it was scheduled rather than discretionary. His holdings decreased by 6.5% to 63,647 shares post-transaction. At the current price of $210.03, the stock is trading 22.0% below its 52-week high of $269.44. His prior sales at STE showed mixed near-term outcomes (30-day range -2.4% to -1.8%), while his cross-ticker track record across 3 prior sells averaged -2.1% over 30 days and -0.1% over 90 days.

Sr. VP Life Sciences Julia Madsen sells 5,008 shares of STERIS (STE) for $1,312,096.00 on 2025-11-21

Madsen executed 2 separate sales totaling 5,008 shares for $1,312,096.00 at $262.00 per share, reducing her holdings by 31.9% from 15,718 to 10,710 shares. The sale occurred near the 52-week high of $267.99, with the stock up 11.2% over 30 days and 7.6% over 90 days, reflecting strong recent price momentum. The company is trading at a P/E of 38.20 with latest-quarter revenue of $1,460,300,000.00 and net income of $191,900,000.00, consistent with solid operational performance. The substantial reduction in her position warrants monitoring to determine whether this reflects portfolio adjustment or a material shift in conviction at the company.

V.P. & Corporate Treasurer Tamaro Renato sold 5,036 shares of STERIS (STE) for $1,297,039.68 across 3 transactions on 2025-11-18, reducing holdings by -46.9%

Tamaro Renato, V.P. & Corporate Treasurer at STERIS plc, executed 3 separate sales totaling 5,036 shares for $1,297,039.68 at a blended average price of $257.55, reducing his stake from 10,731 shares to 5,695 shares. The sales occurred near the company's 52-week high ($267.99), with the current price at $256.98 sitting -4.1% below that peak. His prior sale at this ticker on 2025-08-20 posted a +3.1% 90-day return, indicating that earlier trade did not precede a decline—a timing outcome that mirrors his broader cross-ticker track record, which shows 0.00% well-timed rate on 1 prior sell. The fundamentals show revenue of $1,460,300,000.00 and a P/E of 36.66, reflecting a richly valued position. This substantial reduction in insider holdings—divesting nearly half his stake—combined with execution near a 52-week peak, warrants monitoring of any subsequent company guidance or earnings developments.

Sr. VP & General Counsel Zangerle sold 15,000 STE shares at $265.14 (11 Nov); holdings now 33,669 shares post-transaction.

Zangerle, STERIS's Sr. VP, General Counsel, and Secretary, executed a sale of 15,000 shares at $265.14 on 2025-11-11, reducing his holdings from 48,669 shares to 33,669 shares—a reduction of 30.8% of his pre-transaction position. The sale occurred near the 52-week high ($267.99), with the stock currently trading at $260.44. STERIS is a mature-stage company with $1.5B in quarterly revenue, a 37.15 P/E, and a $25.6B market cap, indicating an established business without growth distress signals. No prior trade history, scheduled plan disclosures, or material business developments are referenced that would contextualize timing or motivation for this sale. The transaction is within bounds of normal executive portfolio activity but the magnitude (one-third of holdings) and proximity to 52-week highs merit tracking to assess whether this represents a broader insider sentiment shift at the company level.

VP & Corporate Treasurer Renato sold 3,204 shares of STE at $249.24 on 2025-08-20, reducing holdings from 10,425 to 7,221 shares (-30.7%).

Renato, the VP & Corporate Treasurer, executed a significant reduction in his STERIS position, selling 3,204 shares (valued at $798,564.96) near the 52-week high of $252.55, with the current price at $251.87 now 0.3% from that peak. The sale represents a -30.7% reduction of his prior holdings from 10,425 to 7,221 shares, a material trimming of concentrated exposure. This transaction occurred in a context where the stock has appreciated +11.7% in 30 days and +3.6% in 90 days, while the company maintains solid fundamentals with $1.4B quarterly revenue and 6.2% annual revenue growth, though the elevated P/E of 38.34 reflects a premium valuation environment.

VP & CAO Karen L Burton sold 7,900 shares of STE at $241.73 (1.9M); holds 6.0K shares post-sale

Karen L Burton, VP & Chief Administrative Officer, sold 7,900 shares (56.9% of her pre-transaction holdings) on 2025-08-11 at $241.73, reducing her position from 13.9K to 6.0K shares. The transaction occurred at a price only 3.5% below the 52-week high of $252.55, and the stock has gained 6.9% over the prior 30 days and 7.2% over 90 days. With STE trading at a P/E of 37.10 and the company posting quarterly revenue of $1.4B with net income of $177.4M (annual revenue growth of 6.2%), this represents a substantial reduction in Burton's direct equity stake at a relatively elevated valuation relative to recent company performance.

STERIS CEO Carestio sells 17,626 shares for $4,275,338.34 via pre-arranged 10b5-1 plan

President and CEO Daniel A Carestio executed 3 separate sales totaling 17,626 shares for $4,275,338.34 on 2025-06-05, reducing his holdings from 69,011 shares to 51,385 shares. This sale was executed pursuant to a pre-arranged 10b5-1 trading plan, meaning it was scheduled rather than discretionary. The transaction reduced his equity stake by 25.5% of his pre-transaction holdings. As a scheduled plan transaction, this represents a predetermined reduction in equity exposure rather than a discretionary trading signal.

SVP Healthcare at STERIS sold 12,828 shares for $3.2M; reduced stake 53% to 11,372 shares post-transaction

Majors Cary L, SVP and President of Healthcare at STERIS, executed 2 separate sales on 2025-05-20 totaling 12,828 shares for $3,208,025.82 at a blended average price of $250.08, reducing his shareholding from 24,200 shares to 11,372 shares—a 53% reduction in holdings. The sales occurred near the 52-week high of $252.55, with current price at $243.80. His prior STE-specific transaction history shows minimal evidence of well-timed selling: his single prior sale at this ticker on 2024-06-05 was followed by a 90-day return of +5.9%, meaning the stock rose after he sold, indicating the prior trade was not well-timed. The substantial reduction in absolute share count and percentage of holdings, combined with execution at elevated price levels relative to the 52-week range, represents a material shift in insider exposure to the company.

STE CFO TOKICH sold 23,332 shares for $5,714,642.92 via 10b5-1 plan; post-sale holdings 42,930 shares

TOKICH MICHAEL J, who was CFO at the time, executed 5 separate sales totaling 23,332 shares for $5,714,642.92 across two trading days (September 13–16, 2024) at prices ranging from $243.53 to $248.02, with a blended average of $244.93. This transaction is part of a pre-arranged 10b5-1 trading plan, meaning the sales were scheduled rather than discretionary. Post-transaction holdings were reduced to 42,930 shares, representing a -35.2% reduction in his shareholding relative to the pre-transaction level of 66,262 shares. As a scheduled divestiture under a 10b5-1 plan, this sale reflects a predetermined execution rather than a contemporaneous market decision.

TOKICH, then-CFO of STERIS (STE), sold 23,332 shares ($5.8M) under 10b5-1 plan on 2024-09-10

TOKICH MICHAEL J, who was CFO of STERIS at the time, sold 23,332 shares at $247.00 on 2024-09-10 under a pre-arranged 10b5-1 trading plan, reducing his holdings from 66,262 to 42,930 shares. As a scheduled transaction, this sale reflects contractual execution rather than discretionary decision-making at a particular market moment. The -35.2% reduction in his holdings is material in absolute terms, though the pre-arranged nature precludes timing-based inference. The fact that TOKICH is no longer serving as the company's current CFO adds context to this transaction—it may reflect planned liquidity during or after a transition in role.